25 Million Seniors Face Higher Drug Premiums as Trump Ends Medicare Subsidy

On July 28, 2026, the Trump administration announced it will end the Part D Premium Stabilization Demonstration after 2026, a Medicare drug-plan premium subsidy that has held down monthly costs⁠4⁠6⁠7⁠11. Reuters first reported the plan that day, and the Centers for Medicare and Medicaid Services confirmed the demonstration would expire after this year⁠4⁠6⁠7. Coverage followed across July 29 and 30 from the Associated Press, ABC News, USA Today, Newsweek, NPR member stations and fact-checkers⁠2⁠3⁠5⁠6⁠8⁠9⁠11. Fortune picked up the political stakes on July 31 with a focus on 25 million seniors and the coming midterms⁠10.

The program at issue was created by the Biden administration two years earlier, in 2024, to blunt premium spikes in Medicare Part D⁠6⁠7⁠9. In practice it paid insurers billions of dollars to keep premiums artificially steady while broader changes to drug coverage phased in⁠6⁠7⁠9. It was always labeled a demonstration, a temporary cushion rather than a permanent benefit, but for enrollees it functioned like one: lower premiums on the bill they actually saw⁠6⁠7.

Medicare Part D itself is not ending⁠5. What ends is only the extra federal payment that suppressed premiums⁠5. That distinction has been lost in some of the alarm since the announcement, but it matters for what happens next⁠5. Drug coverage continues, plans continue, and the federal subsidy built into Part D continues⁠5. The stabilization layer on top of it goes away.

The administration, through CMS Administrator Dr. Mehmet Oz, argued the subsidies are no longer needed⁠2. The paraphrased position in AP-based reporting is that premiums will rise by less than $10 a month for most recipients once the cushion is removed⁠2⁠10. No source excerpt in the reporting file provides the full verbatim text of the official statement, so only that paraphrased projection can be reported as sourced⁠2⁠10. AP-based summaries also cite an average benefit of about $36 a month under the demonstration, again as a reported figure rather than a word-for-word official quote⁠2⁠10.

The other half of the administration case is about who really benefited⁠3⁠9. Officials claimed the program benefited insurance corporations and blamed the prior administration for bailing out insurers with government subsidies⁠3⁠9. That framing turns a seniors-cost story into a waste-and-bailout story: Washington paid private plans to hide the true price, and removing the payment restores discipline⁠3⁠9. Whether insurers simply pocketed stability money or passed it through to enrollees in lower premiums is the unresolved empirical question underneath the rhetoric⁠6⁠7⁠9.

What is certain is that no senior can price 2027 today⁠2⁠5. Beneficiaries will not know their exact premium increases until the fall, when plans announce 2027 rates⁠2⁠5. That lag between announcement and price tag is what creates the uncertainty now dominating coverage⁠2⁠5. A national decision is final, but its household meaning is still blank⁠2⁠5.

Insurers, for their part, have not yet shown their hand in this reporting file⁠2⁠5. Part D premiums are set plan by plan, county by county, with formularies, deductibles and pharmacy networks all moving at once⁠2⁠5. A national average, whether about $36 in past help or under $10 in future pain, tells an individual enrollee very little about the letter coming in October⁠2⁠10. Some plans may absorb more of the loss to retain members, others may pass it straight through, and low-income subsidy recipients face different math entirely⁠2⁠5. None of that will be visible until filings become premiums.

The timing amplifies the fog⁠10. Fortune explicitly framed the rollback as a gift for 25 million seniors right before the midterms, meaning cost hikes landing just as campaigns peak⁠10. That is political analysis, not a premium forecast, but it captures why July news matters for November voting⁠10. Seniors vote at higher rates than any other age group, and drug costs are among the few kitchen-table issues every voter understands without explanation⁠10. An increase that looks modest in a CMS spreadsheet can feel different on a fixed income⁠2⁠10.

There is also history here⁠6⁠7⁠9. The demonstration was created to prevent sticker shock as Medicare drug reforms took effect, shifting costs and risks among government, plans and enrollees⁠6⁠7⁠9. Supporters saw it as responsible transition policy: pay a little now to avoid chaos later⁠6⁠7⁠9. Critics, including the current administration, saw it as masking true costs and subsidizing private companies with public money⁠3⁠9. Ending it does not resolve that debate, it simply decides who learns the true price first⁠3⁠9.

For now the story is a number without a price⁠2⁠5⁠10. Twenty-five million people have been told help is ending, told the hit should be small, and told to wait until fall to learn what small means for them⁠2⁠5⁠10. That is the scale to keep in mind: not a pilot program in a binder, but the largest drug-insurance audience in the country waiting for mail⁠2⁠10.